Results 211 to 220 of about 29,053 (244)
Some of the next articles are maybe not open access.
Radionuclides and therapy of thyroid cancer
Nuclear Medicine Communications, 1993The majority of thyroid carcinomas are removed surgically. The appropriate surgical technique is still debated. After surgery the amount of residual thyroid or tumour and the presence of local or distant metastases is often in doubt, particularly if it is not detectable clinically. Therefore, methods for determining the presence of disease or the later
O'Doherty, M J, Nunan, T O, Croft, D N
openaire +3 more sources
Radionuclide Therapy and Immunomodulation
2021External beam radiation therapy (EBRT) stands as one of the pillars of cancer treatment around the world and has been widely used for decades as a curative and palliative therapy. For most of that time, the prevailing explanation for its antitumor effect has been the induction of complex DNA damage leading to cell death.
Rachel Anderson, Katherine A. Vallis
openaire +2 more sources
2022
Prostate cancer is the most common cancer in the males. It ranks second in cancer-related deaths in the males [1]. The most common symptoms are frequent urination, difficulty in urinating, dysuria, nocturia, and hematuria even though most patients with early prostate cancer are asymptomatic.
SEMİZ, HÜSEYİN SALİH, ÖZTOP, İLHAN
openaire +4 more sources
Prostate cancer is the most common cancer in the males. It ranks second in cancer-related deaths in the males [1]. The most common symptoms are frequent urination, difficulty in urinating, dysuria, nocturia, and hematuria even though most patients with early prostate cancer are asymptomatic.
SEMİZ, HÜSEYİN SALİH, ÖZTOP, İLHAN
openaire +4 more sources
Radionuclide therapy of the thyroid
European Journal of Nuclear Medicine, 1991Radionuclide therapy has a proven place in the management of patients with thyroid disease. Iodine-131 therapy has been established as both successful and safe in treating patients with thyrotoxicosis and thyroid malignancy. Protocols for patient treatment are now standardised, although some variation in practice exists across Europe.
openaire +3 more sources
Recent advances in radionuclide therapy
Seminars in Nuclear Medicine, 2001A variety of radionuclides continue to be investigated and/or clinically used for different therapeutic applications in nuclear medicine. The choice of a particular radionuclide with regard to appropriate emissions, linear energy transfer, and physical half-life is dictated to a large extent by the character of the disease (eg, solid tumor or ...
Ekaterina Dadachova +3 more
openaire +3 more sources
Radionuclide therapy revisited
European Journal of Nuclear Medicine, 1991Apart from its use in endocrinology and rheumatology, therapeutic nuclear medicine is developing rapidly as an additional treatment modality in oncology. Many different specific tumour-seeking radiopharmaceuticals are being applied both for diagnostic scintigraphy and treatment, using multiple routes and mechanisms to target radionuclides at tumours ...
openaire +3 more sources
Annals of Nuclear Medicine, 1998
Therapeutic nuclear medicine is rapidly developing as an additional treatment modality in oncology. Its unique characteristics are the systemic, yet selective delivery of radiation doses in target tissues, its non-invasiveness, the relative lack of immediate and late side effects, and the advantage that uptake and retention in the tumor can be pre ...
openaire +3 more sources
Therapeutic nuclear medicine is rapidly developing as an additional treatment modality in oncology. Its unique characteristics are the systemic, yet selective delivery of radiation doses in target tissues, its non-invasiveness, the relative lack of immediate and late side effects, and the advantage that uptake and retention in the tumor can be pre ...
openaire +3 more sources
Radionuclide Therapy for Neuroendocrine Tumors
Current Oncology Reports, 2017Peptide receptor radionuclide therapy (PRRT) is a form of systemic radiotherapy that allows targeted delivery of radionuclides to tumor cells expressing high levels of somatostatin receptors. The two radiopeptides most commonly used for PRRT, 90Y-DOTATOC and 177Lu-DOTATATE, have been successfully employed for more than a decade for the treatment of ...
CIVES, MAURO, Strosberg, Jonathan
openaire +4 more sources
Targeted Radionuclide Therapy of Melanoma
Seminars in Nuclear Medicine, 2016An estimated 60,000 individuals in the United States and 132,000 worldwide are yearly diagnosed with melanoma. Until recently, treatment options for patients with stages III-IV metastatic disease were limited and offered marginal, if any, improvement in overall survival. The situation changed with the introduction of B-RAF inhibitors and anti-cytotoxic
Ekaterina Dadachova, Abdullah Norain
openaire +2 more sources
Radionuclide therapy of hematologic disorders [PDF]
Seminars in Nuclear Medicine, 1979 32P is effective therapy for polycythemia and primary thrombocytosis. The Polycythemia Vera Study Group is comparing radioactive phosphorus with alkylating agents to determine relative efficacy. Less well investigated is the effectiveness of 32P vs. busulfan in chronic granulocytic leukemia. Endolymphatic administration of radiopharmaceuticals may play
openaire +2 more sources